Arcturus Therapeutics, Inc. is a biotechnology company specializing in RNA medicines. The company focuses on developing innovative treatments using RNA-based technologies, which involve manipulating RNA (a molecule essential for coding, decoding, regulation, and expression of genes) to treat various diseases. Arcturus operates primarily in the pharmaceutical and biotechnology markets, targeting both rare genetic disorders and infectious diseases.

The company serves a diverse range of clients, including healthcare providers, research institutions, and government agencies. One of its notable projects is the development of a COVID-19 mRNA vaccine candidate, LUNAR-COV19 (ARCT-021), which has shown promising results in early clinical trials. Additionally, Arcturus is working on treatments for genetic conditions such as Ornithine Transcarbamylase (OTC) deficiency, with its ARCT-810 program.

Arcturus' business model revolves around research and development (R&D) of RNA-based therapies, followed by clinical trials to test their safety and efficacy. The company generates revenue through various channels, including public and private funding, partnerships with other pharmaceutical companies, and government contracts. For instance, Arcturus has secured significant financial commitments from Singapore for its COVID-19 vaccine development.

The company also engages in strategic collaborations to enhance its manufacturing capabilities and expand its market reach. An example is its agreement with Recipharm to support the production of its vaccine candidate.

In summary, Arcturus Therapeutics is a cutting-edge biotech firm leveraging RNA technology to develop treatments for genetic disorders and infectious diseases, with a robust pipeline of products in various stages of development.

Keywords: RNA medicines, biotechnology, genetic disorders, infectious diseases, mRNA vaccine, clinical trials, pharmaceutical, healthcare, research, development.